Tianjin Medical Journal ›› 2026, Vol. 54 ›› Issue (1): 108-112.doi: 10.11958/20252288

• Review • Previous Articles    

Research progress of aldehyde dehydrogenase 2 gene polymorphism in coronary heart disease

WU Wenwei(), QIU Miaoling, ZHU Haikun, LUO Rong()   

  1. Department of Anesthesiology I, Meizhou People's Hospital, Meizhou 514031, China
  • Received:2025-06-19 Revised:2025-09-16 Published:2026-01-15 Online:2026-01-19
  • Contact: E-mail:luorong0613@163.com

Abstract:

Coronary heart disease (CHD) is a common clinical condition in cardiology, characterized by atherosclerotic lesions in coronary arteries leading to luminal stenosis or occlusion, which subsequently causes myocardial ischemia, hypoxia and even necrosis. Known risk factors only partially account for the pathogenesis of CHD, suggesting the involvement of other critical pathogenic mechanisms. Aldehyde dehydrogenase 2 (ALDH2), as a key mitochondrial metabolic enzyme, is widely expressed in various tissues of human body. Its activity is significantly regulated by gene polymorphisms, especially demonstrating protective effects in cardiovascular diseases including heart failure and CHD. The pathogenesis of CHD involves the interaction of multiple factors, and its occurrence and development involve the interaction between genetic susceptibility and environmental risk factors. However, the specific mechanism by which ALDH2 plays a role in this has not yet been clarified. This review summarizes the potential molecular mechanisms between ALDH2 gene polymorphisms and the onset and progression of CHD, aiming to provide theoretical references for the prevention and treatment of CHD.

Key words: coronary heart disease, ethanol, polymorphism, genetic, aldehyde dehydrogenase 2

CLC Number: